Note: Ingredients listed on restricted chemical lists
EC/CAS
9004-65-3
Name of the chemical
methylhydroxypropylcellulose
Concentration
N/A
EC/CAS
1310-73-2
Name of the chemical
sodium hydroxide
Concentration
N/A
General Information
Revision date
2019-11-08
Product name
Ranolazine Extended-Release Tablets 500mg/1000mg
Chemical name
1-piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2- methoxyphenoxy)propyl]
1.2.1 Relevant identified uses
Therapeutic Category Ranolazine is indicated for the treatment of chronic angina
1.2.2. Uses advised against
Ranolazine is contraindicated in patients
Emergency telephone
Ranolazine extended-release tablets are available as a film-coated, non-scored, extended-release tablet
Icons in SDS
Company Information
company name
Cadila Healthcare Limited
Section 2
SECTION 2: Hazards identification
Dose and Administration Initiate Ranolazine dosing at 500 mg twice daily and increase to 1000 mg twice daily, as needed, based on clinical symptoms. Take Ranolazine with or without meals. Swallow Ranolazine tablets whole; do not crush, break, or chew. The maximum recommended daily dose of Ranolazine is 1000 mg twice daily. If a dose of Ranolazine is missed, take the prescribed dose at the next scheduled time; do not double the next dose. Dose adjustments may be needed when Ranolazine is taken in combination with certain other drugs. Limit the maximum dose of Ranolazine to 500 mg twice daily in patients on moderate CYP3A inhibitors such as diltiazem, verapamil, and erythromycin. Use of Ranolazine with strong CYP3A inhibitors is contraindicated. Use of P-gp inhibitors, such as cyclosporine, may increase exposure to Ranolazine. Titrate Ranolazine based on clinical response. Adverse Effects The following additional adverse reactions occurred at an incidence of 0.5 to 4.0% in patients treated with Ranolazine and were more frequent than the incidence observed in placebo-treated patients: Cardiac Disorders – bradycardia, palpitations Ear and Labyrinth Disorders – tinnitus, vertigo Eye Disorders – blurred vision GI Disorders– abdominal pain, dry mouth, vomiting, dyspepsia General Disorders & Administrative Site Adverse Events– asthenia, peripheral edema Metabolism and Nutrition Disorders – anorexia Nervous System Disorders – syncope (vasovagal) Psychiatric Disorders – confusional state Renal and Urinary Disorders – hematuria Respiratory, Thoracic, and Mediastinal Disorders – dyspnea Skin and Subcutaneous Tissue Disorders – hyperhidrosis Vascular Disorders – hypotension, orthostatic hypotension Over Dose Effect High oral doses of Ranolazine produce dose-related increases in dizziness, nausea, and vomiting. High intravenous exposure also produces diplopia, paresthesia, confusion, and syncope. In addition to general supportive measures, continuous ECG monitoring may be warranted in the event of overdose. Severe tremor, unsteady gait/incoordination, dysphasia, and hallucinations have been reported in cases of overdose with Ranolazine. Since Ranolazine is about 62% bound to plasma proteins, hemodialysis is unlikely to be effective in clearing Ranolazine. Contraindications Ranolazine is contraindicated in patients: • Taking strong inhibitors of CYP3A • Taking inducers of CYP3A • With liver cirrhosis Pregnancy Comments Studies in rats and rabbits showed no evidence of fetal harm at exposures 4 times the maximum recommended human dose. In the U.S. general population, the estimated background risk of major birth defects and of miscarriage of clinically recognized pregnancies is 2-4% and 15- 20%, respectively. Embryofetal toxicity studies were conducted in rats and rabbits orally administered Ranolazine during organogenesis. In rats, decreased fetal weight and reduced ossification were observed at doses (corresponding to 4-fold the AUC for the MRHD) that caused maternal weight loss. No adverse fetal effects were observed in either species exposed (AUC) to Ranolazine at exposures (AUC) equal to the MRHD.